



# BETA DRUGS LIMITED

**BDL/PKL/SEC/2025**  
**24<sup>th</sup> January, 2025**

National Stock Exchange of India Ltd.  
Exchange Plaza, 5th Floor  
Plot no. C/I, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai — 400 051.

## **SYMBOL-BETA**

Dear Sir/Madam,

Sub: Compliance of circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 issued by Securities and Exchange Board of India (SEBI) dated December 31, 2024.

In compliance with Regulations 13(3) and 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated December 31, 2024; we are attaching herewith a Quarterly Integrated Filing (Governance) Report for the quarter ended December 31, 2024 in the prescribed format.

In this regard further note that our company is listed on SME platform therefore regulation 27 (2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the filing of Compliance Report on Corporate Governance on a quarterly basis is not applicable on us.

You are requested to kindly take the same on your record.

Thanking You  
Your's faithfully  
For Beta Drugs Ltd.

**Rajni Brar**

Digitally signed by  
Rajni Brar  
Date: 2025.01.24  
12:40:31 +05'30'

Rajni Brar  
Company Secretary

**CIN No.:** L24230HP2005PLC028969

**Admin. Office :** SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

**Registered Office & Works:** Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

**Website :-** [www.betadrugslimited.com](http://www.betadrugslimited.com)

**E-Mail :-** [info@betadrugslimited.com](mailto:info@betadrugslimited.com)

**A. QUARTERLY INTEGRATED FILING (GOVERNANCE)**

Compliance Report on Corporate Governance on a quarterly basis – Not applicable being company listed on SME Platform

1. Name of the Listed Entity: BETA DRUGS LIMITED

2. Quarter ending: 31/12/2024

**B. INVESTOR GRIEVANCE REDRESSAL REPORT**

Investor Grievance Redressal Report for the quarter ended December 31, 2024	
No. of investor complaints pending at the beginning of Quarter	<b>NIL</b>
No. of investor complaints received during the Quarter	<b>NIL</b>
No. of investor complaints disposed off during the Quarter	<b>NIL</b>
No. of investor complaints those remaining unresolved at the end of the Quarter	<b>NIL</b>

Beta Drugs Limited  
  
Company Secretary  
ACS - 24684

**C. DISCLOSURE OF ACQUISITION OF SHARES OR VOTING RIGHTS IN UNLISTED COMPANIES**

The details of acquisition of shares or voting rights in unlisted companies during the quarter in terms of sub-para 1 of para A of Part A of Schedule III are given below:

Sr. No.	Name of the unlisted company in which shares or voting rights have been acquired	Date of acquisition	Aggregate holding (% shares or voting rights) as at the end of the previous quarter	% shares or voting rights acquired during the quarter	Aggregate holding (% shares or voting rights) as at the end of the quarter
<b>NOT APPLICABLE</b>					

**D. DISCLOSURE OF IMPOSITION OF FINE OR PENALTY**

The details of imposition of fine or penalty during the quarter in terms of sub-para 20 of para A of Part A of Schedule III are given below:

Sr. No.	Name of the authority	Nature and details of the action(s) taken or order(s) passed	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
1.	National Stock Exchange of India Limited	Fine imposed amounting Rs 10,000 +GST 18% only 1 day delay in filing XBRL of voting results of AGM but pdf filed within the timeline.	14/11/2024	Non-compliance with Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015	No such impact

Beta Drugs Limited  
  
Company Secretary  
ACS - 24684

**E. DISCLOSURE OF UPDATES TO ONGOING TAX LITIGATIONS OR DISPUTES**

The updates on tax litigations or disputes in terms of sub-para 8 of para B of Part A of Schedule III read with corresponding provisions of Annexure 18 of the Master Circular are given below:-NA

Sr. No.	Name of the opposing party	Date of initiation of the litigation / dispute	Status of the litigation / dispute as per last disclosure	Current status of the litigation / dispute
-	-	--	-	-

**F. DISCLOSURE OF LOANS / GUARANTEES / COMFORT LETTERS / SECURITIES ETC. (applicable only for half-yearly filings i.e., 2nd and 4th quarter) –Reporting not applicable for this quarter**

**G. AFFIRMATIONS ON COMPLIANCE REQUIREMENTS FOR AGM (applicable only for the first half-year filing i.e., 2nd quarter) –Not applicable for this quarter**

**H. WEBSITE AFFIRMATIONS (applicable only for Annual Filing i.e., 4th quarter) - Not applicable for this quarter**

**I. AFFIRMATIONS W.R.T. COMPLIANCE WITH CORPORATE GOVERNANCE PROVISIONS (applicable only for Annual Filing i.e., 4th quarter) – Not applicable for this quarter**

Beta Drugs Limited  
  
Company Secretary  
ACS - 24684